Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Hepatitis C, HIV, Antibiotics And Vaccines Headline Infectious Diseases Discussion At TAP Conference

This article was originally published in The Pink Sheet Daily

Executive Summary

In developing the infectious diseases track for this year’s Therapeutic Area Partnerships conference, planners focused on areas of unmet medical need, market potential, companies with a diversity of indications, strong science and multi-level partnering opportunities.


Related Content

TREM Rx Pursues New Vaccine Science
Somewhat Late To The HCV Race, Novartis Licenses NS5A Inhibitor From Enanta
Roche Agrees To Acquire HCV Biotech Anadys For $230 Million
Sangamo Brushes Off Phase IIb Diabetic Neuropathy Failure
Rib-X Teams With Sanofi To Develop Novel, Broad-Spectrum Antibiotics
In Advance Of HSV-2 Vaccine Trials, Genocea Taps Investors For $35 Million


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts